• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Clearmind Medicine Inc.

    7/3/25 1:46:27 PM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CMND alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Clearmind Medicine Inc.

    (Name of Issuer)


    Common Shares, no par value

    (Title of Class of Securities)


    185053402

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    185053402


    1Names of Reporting Persons

    AdvisorShares Trust
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    205,933.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    205,933.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    205,933.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.83 %
    12Type of Reporting Person (See Instructions)

    IV


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Clearmind Medicine Inc.
    (b)Address of issuer's principal executive offices:

    101 - 1220 W 6 Avenue, Vancouver, BC, Canada (Federal Level), V6H1A5
    Item 2. 
    (a)Name of person filing:

    AdvisorShares Trust
    (b)Address or principal business office or, if none, residence:

    4800 Montgomery Lane, Suite 150 Bethesda, Maryland 20814
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Shares, no par value
    (e)CUSIP No.:

    185053402
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    205,933
    (b)Percent of class:

    4.83%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    205,933

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    205,933

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    AdvisorShares Trust
     
    Signature:/s/ Stefanie Little
    Name/Title:Stefanie Little - Chief Compliance Officer
    Date:07/03/2025
    Get the next $CMND alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMND

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CMND
    SEC Filings

    View All

    SEC Form 6-K filed by Clearmind Medicine Inc.

    6-K - Clearmind Medicine Inc. (0001892500) (Filer)

    8/7/25 7:37:23 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Clearmind Medicine Inc.

    6-K - Clearmind Medicine Inc. (0001892500) (Filer)

    8/5/25 8:38:19 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Clearmind Medicine Inc.

    6-K - Clearmind Medicine Inc. (0001892500) (Filer)

    7/30/25 8:22:16 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMND
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

    Vancouver, Canada, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) as part of its ongoing collaboration with SciSparc Ltd. (NASDAQ:SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company developing therapies for central nervous system disorders. The patent application published under the European Patent Office covers an innovative combinatio

    8/7/25 7:32:00 AM ET
    $CMND
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

    TEL AVIV, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind") has led to the publication of an international patent application under the Patent Cooperation Treaty (PCT). The patent application published under the European Patent Office covers an innovative combination therapy of Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) for the treatment

    8/7/25 7:32:00 AM ET
    $CMND
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

    IRB Approval from Hadassah Medical Center Follows FDA IND Clearance and Prior Approvals from Additional Clinical Sites Vancouver, Canada, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional Review Board (IRB) approval from Hadassah Medical Center, Jerusalem, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD

    8/5/25 8:15:00 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMND
    Leadership Updates

    Live Leadership Updates

    View All

    Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

    Company entered a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct its first in-human clinical trial Tel Aviv, Israel / Vancouver, Canada, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. is pleased to announce that the company has entered into a Clinical Trial Agreement with Johns Hopkins University School of Medicine, to conduct its Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 as a potential treatment for Alcohol Use Disorder (AUD). The CM-CMND-001 clinical trial is a multinational, multi-center, single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD su

    11/9/23 9:20:00 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam

    Hebrew University of Jerusalem professor is an expert on obesity and metabolic syndrome  Tel Aviv, Israel / Vancouver, Canada, May 08, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND) (CSE:CMND), (FSE: CWY) ("Clearmind" or "the company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has appointed Professor Joseph (Yossi) Tam, D.M.D., Ph.D., to its Scientific Advisory Board ("SAB"). Prof. Tam is the Head of the Obesity and Metabolism Laboratory and the Director of the Multidisciplinary Center for Cannabinoid Research at the Hebrew University of Jerusalem. Prof. Tam is

    5/8/23 8:30:00 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board

    Professor Kranzler is the Benjamin Rush Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania's Perelman School of Medicine Tel Aviv, Israel / Vancouver, Canada, March 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (CSE:CMND), (FSE: CWY) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the appointment of Professor Henry R. Kranzler, M.D., as the newest member of its Scientific Advisory Board ("SAB"). Professor Kranzler is the Benjamin Rush Professor of Psychiatry, an

    3/14/23 8:55:00 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Clearmind Medicine Inc.

    SC 13G/A - Clearmind Medicine Inc. (0001892500) (Subject)

    11/14/24 5:08:52 PM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care